Zimmer Biomet Holdings, Inc. (ZBH)
Automate Your Wheel Strategy on ZBH
With Tiblio's Option Bot, you can configure your own wheel strategy including ZBH - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol ZBH
- Rev/Share 38.7054
- Book/Share 62.362
- PB 1.453
- Debt/Equity 0.579
- CurrentRatio 2.4359
- ROIC 0.0558
- MktCap 17915136400.0
- FreeCF/Share 6.7813
- PFCF 13.2823
- PE 19.718
- Debt/Assets 0.3235
- DivYield 0.0106
- ROE 0.0731
- Rating B+
- Score 3
- Recommendation Neutral
- P/E Score 2
- DCF Score 5
- P/B Score 3
- D/E Score 1
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Upgrade | ZBH | JP Morgan | Neutral | Overweight | $125 | $128 | Dec. 17, 2024 |
| Initiation | ZBH | Wolfe Research | -- | Peer Perform | -- | -- | Sept. 10, 2024 |
News
Why Is Zimmer (ZBH) Down 0.5% Since Last Earnings Report?
Published: June 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Zimmer (ZBH) reported earnings 30 days ago. What's next for the stock?
Read More
We pay attention to policy and patients, says Zimmer Biomet CEO Ivan Tornos
Published: May 20, 2025 by: CNBC Television
Sentiment: Neutral
Ivan Tornos, Zimmer Biomet CEO, joins 'Closing Bell Overtime' from the CNBC CEO Council Summit to talk navigating a changing political landscape, partnering with Arnold Schwarzenegger and more.
Read More
Stifel Has Big Second-Half Stock Market Concerns: 5 Defensive Value Dividend Stocks Buys
Published: May 20, 2025 by: 24/7 Wall Street
Sentiment: Neutral
If there is one voice on Wall Street that we always listen to, it is Stifel's Barry Bannister, and with good reason.
Read More
ZBH Stock to Gain From Buyouts and Innovations Amid Macro Issues
Published: May 19, 2025 by: Zacks Investment Research
Sentiment: Positive
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
Read More
These Analysts Lower Their Forecasts On Zimmer Biomet After Q1 Results
Published: May 06, 2025 by: Benzinga
Sentiment: Neutral
Zimmer Biomet Holdings, Inc ZBH reported better-than-expected earnings for the first quarter on Monday.
Read More
Zimmer Biomet: Stronger Cash Flows Needed Before The Stock Rebounds
Published: May 06, 2025 by: Seeking Alpha
Sentiment: Neutral
Zimmer Biomet's stock dropped nearly 10% on the back of soft Q1 results. Despite structural tailwinds, Zimmer Biomet's business is struggling in the face of high interest rates, trade tensions and competition. Zimmer Biomet's cash flows appear set to be particularly hard hit by tariffs, meaning the company's share price is likely to remain depressed until this is resolved.
Read More
ZBH Q1 Earnings Beat, Operating Margin Dips, Stock Down in Premarket
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Negative
Zimmer Biomet reports solid first-quarter performance across its geographic regions. However, contraction in its operating margin is a concern.
Read More
Zimmer Biomet Holdings, Inc. (ZBH) Q1 2025 Earnings Call Transcript
Published: May 05, 2025 by: Seeking Alpha
Sentiment: Neutral
Zimmer Biomet Holdings, Inc. (NYSE:ZBH ) Q1 2025 Earnings Conference Call May 5, 2025 8:30 AM ET Company Participants David DeMartino - SVP, IR Ivan Tornos - President & CEO Suketu Upadhyay - CFO & EVP, Finance, Operations & Supply Chain Conference Call Participants Robbie Marcus - JPMorgan David Roman - Goldman Sachs Chris Pasquale - Nephron Matthew O'Brien - Piper Sandler Matthew Taylor - Jefferies Larry Biegelsen - Wells Fargo Josh Jennings - TD Cowen Travis Steed - Bank of America Joanne Wuensch - Citi Caitlin Cronin - Canaccord Genuity Richard Newitter - Truist Securities Shagun Singh - RBC …
Read More
Zimmer (ZBH) Q1 Earnings: Taking a Look at Key Metrics Versus Estimates
Published: May 05, 2025 by: Zacks Investment Research
Sentiment: Neutral
While the top- and bottom-line numbers for Zimmer (ZBH) give a sense of how the business performed in the quarter ended March 2025, it could be worth looking at how some of its key metrics compare to Wall Street estimates and year-ago values.
Read More
Insights Into Zimmer (ZBH) Q1: Wall Street Projections for Key Metrics
Published: April 30, 2025 by: Zacks Investment Research
Sentiment: Neutral
Get a deeper insight into the potential performance of Zimmer (ZBH) for the quarter ended March 2025 by going beyond Wall Street's top -and-bottom-line estimates and examining the estimates for some of its key metrics.
Read More
ZBH Stock to Gain From Volume Growth Amid Rising Costs
Published: April 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
Read More
PARAGON 28 INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Paragon 28, Inc. - FNA
Published: April 02, 2025 by: Business Wire
Sentiment: Neutral
NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of Paragon 28, Inc. (NYSE: FNA) to Zimmer Biomet Holdings, Inc. (NYSE: ZBH). Under the terms of the proposed transaction, shareholders of Paragon will receive $13.00 in cash as well as a non-tradeable contingent value right, entitling the holder to receive up to $1.00 per share in cash if certain revenue mileston.
Read More
Zimmer Biomet Focuses on Innovation Amid Growing Competition
Published: March 14, 2025 by: Zacks Investment Research
Sentiment: Negative
Among Zimmer Biomet's knee solutions featured at the AAOS 2025, the newly cleared Persona Revision SoluTion Femur is expected to draw attention.
Read More
ZBH Stock to Gain From Global Expansion Amid Difficult FX Scenario
Published: March 12, 2025 by: Zacks Investment Research
Sentiment: Positive
Zimmer Biomet is strategically expanding its global presence to address the huge demand in the musculoskeletal space.
Read More
ZBH Stock Hurt by Margin Concerns and Difficult Solvency
Published: February 17, 2025 by: Zacks Investment Research
Sentiment: Negative
Zimmer Biomet is suffering due to macroeconomic uncertainties, pricing pressure and unfavorable currency fluctuations.
Read More
About Zimmer Biomet Holdings, Inc. (ZBH)
- IPO Date 2001-07-25
- Website https://www.zimmerbiomet.com
- Industry Medical - Devices
- CEO Mr. Ivan Tornos
- Employees 17000